Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
OBJECTIVE
To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.


METHODS
Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene.


RESULTS
There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006).


CONCLUSIONS
These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine.
Zou
Yan-Feng
YF
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
Wang
Yu
Y
Liu
Ping
P
Feng
Xiao-Liang
XL
Wang
Bin-Yan
BY
Zang
Tong-Hua
TH
Yu
Xin
X
Wei
Jing
J
Liu
Zhong-Chun
ZC
Liu
Ying
Y
Tao
Ming
M
Li
Hui-Chun
HC
Li
Ke-Qing
KQ
Hu
Jian
J
Li
Ming
M
Zhang
Ke-Rang
KR
Ye
Dong-Qing
DQ
Xu
Xi-Ping
XP
D000293:Adolescent; D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D002681:China; D015331:Cohort Studies; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011788:Quality of Life / Q000523:psychology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012919:Social Behavior; D011795:Surveys and Questionnaires; D055815:Young Adult
D019208:Brain-Derived Neurotrophic Factor; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors